Stock Taper
PPBT
PURPLE BIOTECH LTD.
NASDAQ
$1.57
▼ DOWN 0.63% (-0.01)

KEY STATISTICS

Market Cap$216.79 K
52w High$23.60
52w Low$1.16
Dividend Yield
Frequency
P/E-0.08
Volume6.46K
Shares Out.138.08K

COMPANY

LEADERSHIP

Gil Efron
CHIEF EXECUTIVE
Gil Efron

ABOUT

SECTOR
Healthcare
WENT PUBLIC
November 20, 2015
METHOD OF GOING PUBLIC
IPO
FULL TIME EMPLOYEES
10

UPCOMING EARNINGS

DateNov 13, 2026
DayFriday
Rev. Est.
NOV
13
FRI

SPLIT RECORD

DATETYPERATIO
2026-03-02Reverse1:10
2024-09-17Reverse1:20
2020-08-21Reverse1:10

PRICE

$1.57 ▼ DOWN 0.63% (−$0.01)
OVERLAYS
$1.53$1.56$1.599:30 AM10:35 AM11:40 AM12:44 PM1:49 PM2:54 PM3:59 PM1.57

About Purple Biotech Ltd.

https://purple-biotech.com ↗

Purple Biotech Ltd. is a clinical-stage Israeli company developing cancer therapies, including monoclonal antibody CM24 and small molecule NT219, targeting tumor immune evasion in various solid tumors.

INDUSTRY

Biotechnology

A PRODUCT PURPLE BIOTECH LTD. IS KNOWN FOR

IM1240
IM1240

IM1240, Purple Biotech’s tri-specific antibody from the CAPTN-3 platform, targets 5T4 to activate T cells and NK cells against solid tumors, aiming for a potent, safe, and broad anti-cancer immune response.

RATINGS SNAPSHOT

Overall rating: B-

DCFROEROAD/EP/EP/B
Discounted Cash Flow3
Return On Equity1
Return On Assets1
Debt To Equity4
Price To Earnings1
Price To Book5
Overall Score3

INSIDER TRADES

DIRECTOR
Rock Simcha
· —
2026-03-18
DIRECTOR
Rock Simcha
· 2.6M shares
2026-03-18
DIRECTOR
Zilberberg Suzana
· 2.6M shares
2026-03-18
DIRECTOR
Zilberberg Suzana
· —
2026-03-18

MOST RECENT ANALYST GRADES

GRADE SUMMARY
BUY 1
1 GRADES IN THE LAST 12 MONTHS

SECTORS PEERS

PEERPRICE
AKTX$7.85COMPARE
REVB$1.09COMPARE
CDT$2.86COMPARE
DRMA$1.42COMPARE
XAGE$0.28COMPARE
PBM$4.33COMPARE
VINC$0.01COMPARE
SYRS$0.00COMPARE